These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 25907455)
1. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis. Murata S; Aomatsu T; Yoden A; Tamai H Pediatr Int; 2015 Oct; 57(5):942-6. PubMed ID: 25907455 [TBL] [Abstract][Full Text] [Related]
13. Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children. Kong MS; Chen CY Changgeng Yi Xue Za Zhi; 1996 Mar; 19(1):50-4. PubMed ID: 8935375 [TBL] [Abstract][Full Text] [Related]
14. Ceftriaxone-associated Biliary Pseudolithiasis with Elderly Type 1 Diabetes Mellitus: Two Case Reports. Kanazawa K; Suzuki S; Inaba T; Koga S; Kuwabara K Intern Med; 2023 Nov; 62(22):3367-3371. PubMed ID: 37032086 [TBL] [Abstract][Full Text] [Related]
15. Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis. Shima A; Suehiro T; Takii M; Soeda H; Hirakawa M Case Rep Nephrol Dial; 2015; 5(3):187-91. PubMed ID: 26558252 [TBL] [Abstract][Full Text] [Related]
16. Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis. Alemayehu H; Desai AA; Thomas P; Sharp SW; St Peter SD Pediatr Surg Int; 2014 Mar; 30(3):323-6. PubMed ID: 24464035 [TBL] [Abstract][Full Text] [Related]
17. Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections. Tsukagoshi S; Ishizawa K; Hirayanagi K; Nagamine S; Makioka K; Fujita Y; Ikeda Y Intern Med; 2017 Dec; 56(23):3189-3192. PubMed ID: 29021458 [TBL] [Abstract][Full Text] [Related]